Van Berkom & Associates Boosted Hms Hldgs (HMSY) Position; Cellectar Biosciences (CLRB) Shorts Lowered By 0.77%

February 21, 2018 - By mmahotstuff

Van Berkom & Associates Inc increased Hms Hldgs Corp (HMSY) stake by 3.45% reported in 2017Q3 SEC filing. Van Berkom & Associates Inc acquired 121,335 shares as Hms Hldgs Corp (HMSY)’s stock declined 3.70%. The Van Berkom & Associates Inc holds 3.64M shares with $72.28 million value, up from 3.52 million last quarter. Hms Hldgs Corp now has $1.30 billion valuation. The stock increased 1.21% or $0.185 during the last trading session, reaching $15.465. About 497,826 shares traded. HMS Holdings Corp. (NASDAQ:HMSY) has risen 13.44% since February 21, 2017 and is uptrending. It has underperformed by 3.26% the S&P500.

Cellectar Biosciences Inc (NASDAQ:CLRB) had a decrease of 0.77% in short interest. CLRB’s SI was 1.08 million shares in February as released by FINRA. Its down 0.77% from 1.09 million shares previously. With 353,700 avg volume, 3 days are for Cellectar Biosciences Inc (NASDAQ:CLRB)’s short sellers to cover CLRB’s short positions. The stock increased 0.86% or $0.01 during the last trading session, reaching $1.17. About 113,168 shares traded. Cellectar Biosciences, Inc. (NASDAQ:CLRB) has risen 63.81% since February 21, 2017 and is uptrending. It has outperformed by 47.11% the S&P500.

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company has market cap of $18.50 million. The firm offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease. It currently has negative earnings. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.

Since August 24, 2017, it had 0 insider buys, and 2 insider sales for $1.00 million activity. The insider LUCIA WILLIAM C sold $597,880. Another trade for 20,734 shares valued at $366,543 was sold by Neuman Semone. Nustad Cynthia sold $404,004 worth of HMS Holdings Corp. (NASDAQ:HMSY) on Thursday, August 31.

Among 10 analysts covering HMS Holdings (NASDAQ:HMSY), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. HMS Holdings had 25 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, August 18 by Jefferies. The firm has “Neutral” rating given on Monday, November 20 by Cantor Fitzgerald. The rating was upgraded by Oppenheimer on Friday, April 29 to “Outperform”. Jefferies maintained HMS Holdings Corp. (NASDAQ:HMSY) rating on Friday, June 16. Jefferies has “Hold” rating and $21.5000 target. Jefferies maintained it with “Hold” rating and $21.5 target in Monday, August 21 report. The stock of HMS Holdings Corp. (NASDAQ:HMSY) earned “Hold” rating by Jefferies on Tuesday, July 18. The rating was maintained by Robert W. Baird on Friday, November 17 with “Buy”. The company was upgraded on Monday, September 21 by Zacks. The rating was upgraded by Raymond James to “Strong Buy” on Thursday, August 10. Oppenheimer maintained HMS Holdings Corp. (NASDAQ:HMSY) on Friday, August 4 with “Buy” rating.

Van Berkom & Associates Inc decreased Re Max Holdings Inc (NYSE:RMAX) stake by 5,249 shares to 1.12 million valued at $71.18M in 2017Q3. It also reduced Primoris Svcs Corp (NASDAQ:PRIM) stake by 563,159 shares and now owns 1.81M shares. Chemed Corp New (NYSE:CHE) was reduced too.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>